Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsSeth Lerner, MD
Assistant Clinical ProfessorAbout
Research
Publications
2026
A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.
Sadeghi S, Callis S, Lara P, Berg S, Brown J, Ayanambakkam A, Cole S, Kessler E, Vaena D, Angstreich G, Gourdin T, Mar N, Bangs R, Nakagawa D, Daneshmand S, Thompson I, Flaig T, Petrylak D, Lerner S. A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design. Journal Of Clinical Oncology 2026, 44: tps894-tps894. DOI: 10.1200/jco.2026.44.7_suppl.tps894.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaProgression-free survivalPhase III randomized trialStandard of careEnfortumab vedotinOverall survivalPrimary endpointCisplatin-ineligible metastatic urothelial carcinomaMedian progression-free survivalBone only metastasisStudies of eribulinMedian overall survivalPlatinum-based chemotherapyEndpoint of OSOne-sided alphaFGFR3 alterationsMedian OSLiver metastasesSystemic therapyUrothelial carcinomaEligible ptsSecondary endpointsGenitourinary cancersGrade 3Randomized trialsSWOG 2427: Single arm phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT).
Ballas L, Callis S, Daneshmand S, Tripathi A, Hamstra D, Yu J, Tyson M, Mouw K, Meeks J, McConkey D, Rose K, Tawagi K, Mittal K, Sachdev S, Flaig T, Lerner S. SWOG 2427: Single arm phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT). Journal Of Clinical Oncology 2026, 44: tps913-tps913. DOI: 10.1200/jco.2026.44.7_suppl.tps913.Peer-Reviewed Original ResearchClinical complete responsePathological complete responseSingle arm phase II studyResponse to NATYears of pembrolizumabNeoadjuvant therapyMetastasis-free survivalRadical cystectomyBladder preservationComplete responseLocal therapyOverall survivalClinical complete response ratePathologic complete response rateResponse to neoadjuvant therapyMuscle invasive bladder cancerActive systemic therapyBladder preservation rateBladder preservation therapyFractions of radiotherapyEvent-free survivalRecurrence-free survivalInvasive bladder cancerLocal disease recurrencePhase 2 trialA0650 A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302)
Jayram G, Shore N, Salmasi A, Aguilar L, Burn T, Lihou C, Degaonkar V, Goluboff E, Ganapathy D, Lerner S. A0650 A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302). European Urology 2026, 89: s1. DOI: 10.1016/s0302-2838(26)00701-3.Peer-Reviewed Original ResearchToward noninvasive genomic profiling in muscle-invasive bladder cancer using quantitative CT texture analysis.
Boyne A, Anderson R, Liu D, Varghese B, Lei X, Hwang D, King K, Dani K, Cen S, Duddalwar V, Lerner S. Toward noninvasive genomic profiling in muscle-invasive bladder cancer using quantitative CT texture analysis. Journal Of Clinical Oncology 2026, 44: 825-825. DOI: 10.1200/jco.2026.44.7_suppl.825.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerTumor mutational burdenArea under the receiver-operating curveBladder cancerComputed tomographyDNA mutationsGenomic profilingQuantitative CT texture analysisTranscriptome profilingExtraction of quantitative imaging featuresCT-derived radiomic featuresUrothelial bladder cancerCT texture analysisRoutine clinical applicationReceiver-operating curveQuantitative imaging featuresGenomic dataMutational burdenClinically relevant informationMolecular subtypesTumor biologyCancer Imaging ArchivePoor prognosisMolecular alterationsCell cycleSWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660).
Svatek R, Tangen C, Meeks J, Gilbert S, Lotan Y, Tyson M, Crispen P, Delacroix S, Gills J, Daneshmand S, Woods M, Master V, Mark J, Alva A, Bangs R, Nakagawa D, Unger J, Plets M, Thompson I, Lerner S. SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660). Journal Of Clinical Oncology 2026, 44: lba629-lba629. DOI: 10.1200/jco.2026.44.7_suppl.lba629.Peer-Reviewed Original ResearchHigh-grade recurrence-free survivalProgression-free survivalNon-muscle invasive bladder cancerDuration of CRInvasive bladder cancerComplete responsePPD conversionWeekly instillationsTice BCGBladder cancerHigh-grade non-muscle invasive bladder cancerNon-inferiorityBiopsy-proven complete responseNegative purified protein derivativePhase III randomized trialAE ratesAnti-tumor immunityRecurrence-free survivalCo-primary objectivesBCG shortageCR durationIntravesical therapyMedian agePrimary endpointSecondary endpointsA phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302).
Jayram G, Shore N, Salmasi A, Walia A, Aguilar L, Burn T, Lihou C, Degaonkar V, Goluboff E, Ganapathy D, Lerner S. A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302). Journal Of Clinical Oncology 2026, 44: tps886-tps886. DOI: 10.1200/jco.2026.44.7_suppl.tps886.Peer-Reviewed Original ResearchInvasive bladder cancerIntermediate risk non-muscle invasive bladder cancerFibroblast growth factor receptor 3Non-muscle invasive bladder cancerBladder cancerFibroblast growth factor receptor 3 mutationsMuscle invasive bladder cancerInhibitor of fibroblast growth factor receptor 3Adequate organ functionAdvanced urothelial carcinomaPhase 2 multicenterDuration of responseRecurrence-free survivalUpper tract diseaseOpen-label studyPan-FGFR inhibitorMetastatic diseaseInhibitor therapyOpen-labelUrothelial carcinomaProgression of cancerMarker lesionPrimary endpointProstatic urethraSecondary endpointsLUNAR: Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma—A single-arm, open-label phase 1/2 trial.
Lerner S, Traxer O, Osther P, Hesse C, Patschan O, Raymond K, Jakobsen J. LUNAR: Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma—A single-arm, open-label phase 1/2 trial. Journal Of Clinical Oncology 2026, 44: tps906-tps906. DOI: 10.1200/jco.2026.44.7_suppl.tps906.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerFor-cause biopsiesKidney-sparing surgeryNadofaragene firadenovecRenal pelvisUrine cytologyUrothelial carcinomaEfficacy endpointTreatment optionsLow-grade upper tract urothelial carcinomaUrinary excretionAssociated with high local recurrence ratesHigher local recurrence rateReplication-deficient adenoviral vectorHigh-grade urothelial carcinomaUpper tract urothelial carcinomaNon-surgical treatment optionsEfficacy evaluationPhase 1/2 trialDuration of responseLocal recurrence rateNegative urine cytologyInvasive bladder cancerLow-grade tumorsSecondary efficacy endpointsEnfortumab Vedotin plus Pembrolizumab as Perioperative Therapy
Singh P, Lerner S. Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy. The New England Journal Of Medicine 2026 PMID: 41707168, DOI: 10.1056/nejme2515777.Peer-Reviewed Original ResearchInterdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer
Kaufmann E, Aeppli S, Affentranger A, Arnold N, Arnold W, Aschwanden F, Balermpas P, Beyer J, Bieri U, Boormanns J, Cathomas R, De Bari B, Dressler M, Engeler D, Erdmann A, Gallina A, Gomez S, Guckenberger M, Herrmann T, Hermanns T, Lucca I, John H, Kessler T, Klein J, Laouiti M, Lauffer D, Lerner S, Mattei A, Müntener M, Nguyen D, Niederberger P, Papachristofilou A, Prause L, Putora P, Reinhardt K, Salati E, Sèbe P, Shelan M, Sigg S, Strebel R, Templeton A, Vogl U, Wettstein M, Wyler S, Zihler D, Zilli T, Zwahlen D, Roth B, Fankhauser C. Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer. Bladder Cancer 2026, 12: 23523735251410823. PMID: 41550985, PMCID: PMC12811584, DOI: 10.1177/23523735251410823.Peer-Reviewed Original ResearchTrimodality therapyBladder cancerRadical cystectomyFollow-upPersonalized follow-up schedulesRisk-adapted follow-upMuscle-invasive bladder cancerNon-metastatic bladder cancerNational multicentre cohort studyFollow-up durationFollow-up regimensFollow-up protocolFollow-up scheduleMulticentre cohort studyConsensus meetingFollow-up strategiesFunctional follow-upTrimodality treatmentCurative intentOncological surveillanceRadiation oncologyUsage of patientsFunctional complicationsCurative treatmentTreatment optionsAlopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series
Dadabhoy A, Doshi C, Zahir M, Ladi-Seyedian S, Escobar D, Xia L, Schuckman A, Anderson C, Kates M, Agarwal P, Lerner S, Chamie K, Weizer A, Daneshmand S. Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series. Urologic Oncology Seminars And Original Investigations 2026, 44: 110984. PMID: 41529351, DOI: 10.1016/j.urolonc.2025.12.020.Peer-Reviewed Original ResearchConceptsNonmuscle invasive bladder cancerSide effect profilePostoperative doseBacillus Calmette-GuerinUnderreported side effectPost-TURBTHair lossBladder cancerCases of bladder perforationIntravesical bacillus Calmette-GuerinNonmuscle-invasive bladder cancerMulti-institutional case seriesInvasive bladder cancerCancer referral centerProspective multicenter studyFollow-up visitIncidence of alopeciaBladder perforationGemcitabine therapyTransurethral resectionIntravesical gemcitabineUrinary symptomsUrologic oncologistsReferral centerMulticenter study